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Abstract Our everyday professional and personal lives are irrevocably affected by
technologies that search and understand the meaning of data, that store and preserve
important information, and that automate complex computations through algorith-
mic abstraction. People increasingly rely on products from computer companies
such as Google, Apple, Microsoft and IBM, not to mention their spinoffs, apps,
WiFi, iCloud, HTML, smartphones and the like. Countless daily tasks and habits,
from shopping to reading, entertainment, learning and the visual arts, have been
profoundly altered by this technological revolution. Science has also benefited from
this rapid progress in the field of information and computer science and associated
technologies (ICT). For example, the tentative confirmation of the existence of the
Higgs boson (CMS Collaboration et al. Phys Lett B 716:30–61, 2012), made
through a combination of heavy industrial development, internet-based scientific
communication and collaboration, with data federation, integration, mining and
analysis (Rajasekar et al. iRODS primer: integrated rule-oriented data system.
Synthesis lectures on information concepts, retrieval, and services. Morgan &
Claypool, San Rafael, 2010; Chiang et al. BMC Bioinformatics 12:361, 2011;
Marks. New Sci 196:28–29, 2007), has taken our understanding of the structure
of inorganic matter to a new level (Hay et al. The fourth paradigm: data-intensive
scientific discovery. Microsoft, Redmond, WA, 2009). But within this vision of
universal progress, there is one anomaly: the relatively poor exploitation and
application of new ICT techniques in the context of the clinical neurosciences. A
pertinent example is the genetic study of brain diseases and associated bioinfor-
matics methods. Despite a decade of work on clinically well-defined cohorts,
disappointment remains among some that genome-wide association studies
(GWAS) have not solved many questions of disease causation, especially in
psychiatry (Goldstein. N Engl J Med 360:1696–1698, 2009). One question is
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whether we have the appropriate disease categories. Another factor is that gene
expression is affected by environmental and endogenous factors, as is protein
function in different circumstances (think of the effects of age, developmental
stage and nutrition). It is clear that any genetic associations with disease expression
are likely to be highly complex. Why then are the world’s most powerful super-
computers not being deployed with novel algorithms grounded in complexity
mathematics to identify biologically homogeneous disease types, or to understand
the many interactions that lead to the integrated functions that arise from DNA
metabolism, such as cognition? Is it from a lack of appropriate data and methods or
are the reasons related to our current clinical scientific culture?
Introduction
Reductionist methods of hypothesis falsification have dominated science in the last
two centuries, and rightly so, given the major advances in knowledge about the
living and non-living worlds they have afforded. However, there is much evidence
to suggest that a uniquely reductionist approach may be blinkered. Indeed it may
always have been so—think of Linnaean categorization of the plant kingdom as a
scoping exercise prior to a more modern hypothesis-led, genetically based descrip-
tion of plant biology. Darwin had no idea about the physical nature of the hereditary
process he so cleverly deduced (he received one of the few original copies of
Gregor Mendel’s manuscript, but did not read it, judging by the fact that it was
found uncut at his death). Yet he catalogued the animal kingdom, discovering
hidden patterns that gave rise to his theory about adaptive mechanisms and suc-
cessful procreation underlying the evolution of species. But do biomedical granting
agencies fund work that does not express a firm and clear hypothesis? What modern
biomedical grants agency will fund scoping studies involving observation and
classification (though again, perhaps that’s what GWAS studies are)? Outside
epidemiology, such a scenario is difficult to entertain. And in epidemiology, how
many studies emerge from the correlative world of univariate statistics, and how
many founder on inadequate power?
The most powerful means of examining the spread of influenza epidemics is now
achieved by analyzing the geographical spread of incidence posted on Google
(Brownstein et al. 2008; http://www.google.org/flutrends/). This is a real-time
example of the interconnected power of global computing; crowd sourcing is
another (Brabham 2008). How organic matter self-organizes across spatial and
temporal scales to produce the diversity of living, reproducing, adaptive creatures
and their nervous systems is a question that is slowly being addressed with a new
methodological agenda. The complexity of the human brain demands modern
methods that address, describe and quantify interactions in large integrated systems.
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Clinicians need to take note of this trend, both in terms of the science and art of
medicine and also in any effort to rapidly identify and develop effective treatments.
Syndromic Diagnosis
What is the challenge? Firstly, the clinical-pathological paradigm of the last century
and a half, attributed to Broca in the clinical neurosciences, has reached the limits of
its usefulness. Syndromes, composed of groups of symptoms narrated by patients
with varying degrees of cognitive impairment, or by their relatives, to individual
practitioners, overlap too much to remain useful as a basis for the precise diagnosis
of brain diseases. This is not a new insight, as demonstrated by the variability in
presentation of diseases such as syphilis and diabetes mellitus, but it is an increas-
ingly pertinent one. Recently it has been reported that the five major classes of
psychiatric illness share a similar set of associated genes that predispose not to one
or other class but to mental illness in general (Cross-Disorder Group of the
Psychiatric Genomics Consortium 2004). The spinocerebellar ataxias are associ-
ated with well over 20 dominant, often partially penetrant, mutations, each of which
generates a similar pattern of clinical features, at times causing diagnostic confu-
sion (Sch€ols et al. 2012). The dementia syndrome is caused by a range of patho-
logical mechanisms, a few of which are genetically determined, the vast majority of
which are of unknown aetiology, to the extent that the diagnosis of Alzheimer’s
disease (AD) is wrong in the best centers about 30 % of the time, if post mortem
features are used to define disease (Beach et al. 2012). Longitudinal syndromic
studies demonstrate that even diagnoses of “pure” syndromes fail to remain appli-
cable through life, and correlation with post mortem features is poor if not random
(Kertesz et al. 2005). Finally, the same single genetic mutation can present with a
variety of syndromes. A simple example is that of Huntington’s disease, where a
behavioral or psychiatric presentation is recognized, as are presentations with
movement disorders or gait abnormalities. Though the phenomenon of generational
anticipation in male presentation of the disease is associated with the length of CAG
repeats in the huntingtin gene, it is not understood how this happens. In short, there
is a pressing need to move from an observational and simple correlational approach
to clinical neuroscience to one that is mechanistic and multifactorial.
A Theory of the Brain
That is easier said than done, for a simple reason. Unlike the materials sciences,
where there is a clear if still often approximate (except at the quantum level)
understanding of the organization of inorganic matter across spatial and temporal
scales, no such theory of living matter is available. However, this is not an
intractable problem with infinite degrees of freedom, as some have suggested.
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The building block of organic matter, DNA, is composed of a limited set of highly
specific base pairs. We have a good understanding of how transcription to RNA and
translation to proteins occur, and what mechanisms control these processes. The
human genome is known and much if not all of the variation in it has been
catalogued. Much of it consists of (mysterious) non-coding sequences. That takes
care of a lot of degrees of freedom and sets parameters on how life itself emerges, as
well as cognition, emotion, perception and action. The rules that determine mech-
anistic interactions at these basic levels are constantly being discovered but remain
unconnected without a global theory of brain organization from the lowest to the
highest levels: from base pairs, to genes, to functional and structural proteins, to
neurons and glia, to cortical columns and subcortical nuclei, to redundant networks
and functioning, learning adapting systems, and eventually to cognition and more.
Each level with its rules constrains the structure and function of the next, more
complex ones. There are many examples of such rules. The Hodgkin-Huxley
equations are the best known and among the oldest (Hodgkin and Huxley 1952).
In principle, then, all the levels of brain organization should eventually become
expressible in terms of mathematical relationships, and that would constitute a
brain theory, or model.
Computers
A decade or two ago, the idea that an inestimable number of simultaneous
non-linear equations could represent a theory of brain organization, if dreamt of
by a few, seemed such an unlikely proposition that it merited no more than a passing
frisson. There were two fundamental problems: how to make the calculations, and
how to amass the data on which to make them. The first problem is largely solved, at
least in principle and partly in practice. The most powerful super-computers
currently available are at the peta-flop level (http://www.top500.org/list/2013/06/).
The IBM roadmap predicts the production of an exascale computer around 2018
(1 1018 flops/s). Extrapolating today’s Blue Brain Project numbers, exascale is
probably the minimum required to simulate the entire brain. This level of perfor-
mance is just sufficient for the simultaneous computation of the present estimate of
the number of equations needed to provide a first holistic version of a brain model,
one that instantiates the nonlinear interactions that give rise to the emergent
properties of living brains. As to data storage, this is a practical problem that has
effectively been solved by cloud computing and distributed storage with appropri-
ate addressing; it is data analysis and aggregation with efficient database queries
that are challenges at this scale.
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Data and Data Mining
Clinical scientists are used to dealing with highly controlled, “clean” data sets,
despite the messy nature of their observational constructs. Hence their data sets are
often small, precious and closely guarded, being a critical part of the discovery
process. This mind set is invalidated by advances in data mining algorithms that
have become commonplace in industry (banking, nuclear power, air transportation,
space and meteorology, to name but a few) (http://en.wikipedia.org/wiki/Data_
mining).
Such algorithms identify patterns in big data that are characterized by invariable
clusters of (mathematical) rules. In other words, they are rule-based classifiers.
They offer a potential escape from the world of correlations into the world of
causes. However, strictly, rule-based classification generates correlations, not cau-
sality (although it depends on how narrowly causality is defined). It shows what
occurs together but not what causes what. Homogeneous clusters are useful for
disease signatures, but for treatments causality will have to be understood by
integration of knowledge and simulation results from genetics, biochemistry, phys-
iology and medical description into randomized experiments (Fig. 1).
These powerful and computer-sensitive, data-hungry algorithms often use novel
mathematics. They have been developed because the new generations of computers
can verify and validate them. They deal with multivariate and “dirty” data, missing
data, textual or semantic data and data from different sources or with different
ranges. They can work in non-linear, non-Euclidean, non-stochastic, high-dimen-
sional spaces (Loucoubar et al. 2013). Others are more statistically based, such as
machine learning techniques. Some attempt to exhaustively test all possible models
describing the data to discover the most parsimonious set that explains them. Which
will be the best tools and methods for use in the clinical neurosciences is not yet
clear, but one can be sure that data mining will generate many hypotheses for
testing! And so the perspective emerges that the comprehension of brain organiza-
tion and the causes of brain disease are not to be found by a reductionist approach
alone but by a combination of hypothesis falsification that follows a constructivist,
simulation-based approach using novel classifiers working on large amounts of real
biological data.
Simulating the Brain
An initial proof-of-concept program has recently communicated very encouraging
results. The Blue Brain Project (http://bluebrain.epfl.ch) at the Brain Mind Institute
of the Ecole Polytechnique Fe´de´rale de Lausanne (EPFL) took as its starting point
data on the functionality of ion channels and their distributions along axons and
dendrites of different neural types (Peck and Markram 2008; Khazen et al. 2012).
Proceeding with a simulation-based approach, using biological data about matters
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such as cortical volume, the distribution of cortical layers, the distribution of
capillaries, the variation in numbers and distributions of morphological and func-
tional types of neurons in the various cortical layers, and statistical data on the
probability of connections between different cell types, it built a preliminary model
of a rodent cortical column using an IBM Blue Gene/Q computer. A correspon-
dence of functionality and morphology between the model and ex vivo slices of
brain tissue has been demonstrated (Ramaswamy et al. 2012). Predictions about the
distribution of synaptic connections (Hill et al. 2012) and the occurrence of
spontaneous activity (in the gamma band) have also been made that in themselves
constitute strong hypotheses for further empirical verification.
Fig. 1 Schematic representation of steps in applying modern informatics to clinical neuroscience.
The Human Brain Project (HBP) aims to collect, explain and simulate the functions of the human
brain at different levels of hierarchical complexity. Within the HBP framework, a strategically
feasible approach to understand brain diseases is depicted in this figure. The idea is to federate
(1) and integrate (2) the data, thus making use of an abundance of biological information from the
different levels of brain organisation. Data mining (3) will be used to extract sets of rules that
constitute definitions of homogeneous groupings of patients or subjects. Causal modelling with
new data (real or simulated) will be performed for external validation (4), which will complete the
process of defining (5) the biological signatures of diseases. The signatures of diseases will
constitute the basis for a new, biologically determined nosology that should facilitate drug target
identification and selection of homogeneous groups of patients for clinical trials as well as
simulation of the effects of pharmacological treatment and secondary event profiles
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Data Provenance
The computing power needed for the extension of such a project to whole brains is
now within our reach. Data provenance remains a problem. In the research domain,
there are 30 years of data described in millions of scientific papers lodged in
repositories such as the National Library of Science in Washington DC. There are
many basic science laboratory databases, often publically funded, held in univer-
sities and research laboratories around the world. These data have often been used
once and exist for archival reasons alone. In the clinical field, there are databases in
each hospital that contain clinical and diagnostic information on innumerable
patients. Again, the data are used for the benefit of an individual and are normally
kept for medico-legal reasons or as a baseline for returning patients. In countries
with socialized medicine, these data are paid for by taxes and so, at least in part,
belong to the public. This mass of legacy data represents an enormous, untapped
research resource. How can such heterogeneous data be usefully exploited?
Real-time data addressing is a fact of life for anyone who uses the Internet and a
search engine today. Therefore, in principle, the infrastructure and software are
available. It remains to be seen whether specialized integrated hardware and
software infrastructures will become acceptable to hospitals and researchers for
scientific activity. Issues such as privacy protection in the context of anonymization
are technically solvable and already acceptable on the grounds of proportionality
(the potential benefit to members of society as a whole, compared to the potential
risk to an individual) in worlds such as those of Internet banking and crime
prevention (http://www.scienceeurope.org/uploads/Public%20documents%20and
%20speeches/ScienceEuropeMedicalPaper.pdf; but see Gymrek et al. 2012). Fol-
lowing the CERN model, asking for scientists’ data in return for giving them access
to many other databases should be a huge incentive, especially since it will
accelerate the process of scientific discovery by increasing the efficiency of data
usage. The acceptability of such systems will depend on their ability to avoid
displacement and corruption of source data, which is already a practical possibility
(Alagiannis et al. 2012; Fig. 2). The advantage to society is that taxpayers will
contribute to medical research at no extra cost while benefiting from its fruits. In
other words, every datum collected in the course of standard medical care will also
serve to promote medical and health research based on big data (Marx 2013).
Disease Signatures
Initially, the strategy is to federate data through a dedicated, connected infrastruc-
ture and then to integrate them appropriately so that they can be mined for answers
to specific questions. In all cases the results will relate to groups and not to
individuals, so guaranteeing an appropriate and proportionate degree of privacy.
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“The Human Brain Project,” awarded one billion euros in a European Commis-
sion Flagship of Enterprise and Technology competition in 2013, seeks to use this
strategy in its medical informatics division (http://www.humanbrainproject.eu/#).
One type of question will involve identifying groups of patients who show identical
patterns of biological abnormality based on the results of clinical investigation.
These patterns, called “disease signatures,” will comprise sets of causative features
including clinical findings, results of validated questionnaires of mood and emo-
tion, brain images of various types, electrophysiological recordings, blood tests,
genotypic characteristics, and protein composition of cerebrospinal fluid or blood.
To obtain maximal differentiation and sensitive discrimination between different
diseases, the strategy will be to use data from as wide and inclusive a range of brain
diseases (both neurological and psychiatric) as possible. This approach runs directly
counter to standard techniques of epidemiology based on tightly defined syndromes
or single characteristics, such as a unique pattern of single nucleotide polymor-
phisms or protein expression, by seeking to understand and resolve the one syn-
drome—multiple mutations and one mutation—multiple phenotypes problems. The
disease space, sampled in multiple dimensions, each of which is described by a
Fig. 2 Schematic describing the clinical neurosciences big data infra-structure. In the context of
the Human Brain Project, research will be undertaken based on distributed processing of medical
informatics infrastructures. The Medical Informatics Platform will provide a software framework
that allows researchers to query clinical data stored on hospital and laboratory servers, without
moving the data from the servers where they reside and without disproportionately compromising
patient privacy (in situ querying). Tools and data queries will be made available to a participating
community via a web-based technology platform adapted for neuroscientific, clinical, genetic,
epidemiological and pharmacological users. The information made available will include brain
scans of various types, data from electrophysiology, electroencephalography and genotyping,
metabolic, biochemical and hematological profiles and also data from validated clinical instru-
ments. Tools will be designed to aggregate data for analysis by state of the art high-performance
computing that automatically provides a basic descriptive statistical overview as well as advanced
machine learning and discovery tools
164 R. Frackowiak et al.
specific vector of biological variables, will provide a new diagnostic nosology that
is in principle quantitative and expressed by a complete, exclusive set of charac-
teristic clinical features and results.
In the context of a medical consultation, a doctor might take a set of measure-
ments and order a set of tests to provide a results vector, which can be presented to a
database for matching to disease type, a clear step towards personalized medicine.
Biologically characterized diagnostic criteria will facilitate drug trials in that
diagnostic ambiguities in control and disease cohorts will be drastically attenuated,
leading to small groups with reduced error variances and adequate power for drug
discovery in humans. In dementia, as mentioned earlier, the error in AD diagnosis
approaches 30 %. Certain aged normal people have a degree of AD-related path-
ological change, which is compensated for at the behavioral or cognitive level. It is
claimed that 39 % of elderly subjects supposed to be normal show AD pathology
post mortem (Sch€ols et al. 2012). Twenty percent of 80-year-old adults have some
form of recognizable cognitive decline, so the error variance in currently consti-
tuted normal control groups may also be substantial. Clinical trials with groups that
are as inhomogeneous as these are likely to fail, even with specifically targeted
drugs. A search for preclinical abnormality in populations may lead to a definition
of types of “normality” in large enough data sets, and the dementias may become
more usefully defined by shared clinical and biological characteristics.
Data Mining and Medical Data
One data mining tool—Hypercube©—has already been used in medical research
(Loucoubar et al. 2011). We have preliminary data with this algorithm on a set of
200 patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) data-
base (http://www.three-city-study.com/les-publications-scientifiques-de-l-etude-
des-trois-cites.php) and also from a subset of 500 elderly subjects from the 3 Cities
study (http://adni.loni.ucla.edu) and associated image-genetics-clinical-psychology
cohorts followed in France for 10 years. Our analyses are somewhat flawed, in that
the entire disease space is not sampled and the numbers of patients are pitifully
small (though we now have over 6000 donated datasets from the same sources and
from the pharmaceutical company Sanofi-Aventis), but encouraging patterns have
emerged. Of the subjects in the first dataset, 199 of 200 fell into six distinct
subgroups on the basis of “disease signature.” In the second, where substantial
genotyping data were also available, separate, normal-aged groups can be distin-
guished from a number of groups associated with cognitive decline. The largest of
the latter includes APP and ApoE4 in its “disease signature.” Of great interest will
be secondary phenotyping, returning to groups of patients with the same “disease
signature” to identify specific clinical characteristics or variability in them with
factors such as age, which will give further insight into how brain diseases manifest
(Fig. 3).
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Human Brain Project
The Human Brain Project has, in addition to a medical informatics division, a basic
neuroscience component that is charged with creating an in silico blueprint (model)
of the normal human brain. Replacement of normal biological characteristics in
such a model by disease-associated values should, if correct, give an idea after
propagation through the model of what associated functional or structural changes
to expect. Likewise, modifications of parameters induced by a neuromodulator or
other factor should provide ideas about the spectrum of both desired and undesired
effects of any such medication (Harpaz et al. 2013). It may be worth enlarging this
Fig. 3 Theoretical schema describing the relationship between different levels of description and
the role of the disease signature in relating biology to phenomenology. The biological signatures of
diseases are deterministic mathematical constructs that aim to describe both variability at the
phenomenological level (clinical features with symptoms and syndromes) and at the biological
level (genetic, proteomic, etc.). The key property of a biological signature of disease is that it
accounts for the fact that a symptom of brain dysfunction can be due to many biological causes
(one-to-many symptom mapping) and that a biological cause can present with many symptoms
(many-to-one symptom mapping). In reality, the situation is often one of many-to-many mappings
between symptoms and biological causes. With advanced computing power, nearly exhaustive
searches of a data space can be performed to identify sets of rules that describe homogeneous
populations, to explain their biological data and to predict the pattern of symptoms
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perspective to system-based approaches, too (Zhang et al. 2013). In a real sense the
normal brain simulation program and the medical informatics effort will serve to
test each other in a cycle of repeated virtuous iteration until adequate accuracy can
be achieved for medical practice.
Europe has provided funds for a major coordinated effort in this field, supported
by leading edge computer science and technology, which has its own agenda of
using knowledge about human brain organization to inspire novel chip and com-
puter architectures. The aim is to move on from von Neumann digital binary
machines to neuromorphic probabilistic architectures that are much more energy-
efficient (Pfeil et al. 2013; Indiveri et al. 2011). The vision described here is broad
but practical. Its implementation will demand new competencies in medical
researchers and doctors, greater cross-disciplinary collaboration (along the lines
pioneered by physicists in CERN) and major changes in culture and practice.
Clinical Neuroscience-Related Big Data Initiatives
The scientific world is taking on the challenge faced by clinical neuroscience to
create a culture and foster competences that will be needed for the effective use of
big data research (see Box 1 for more details). Examples include BioMedBridges, a
joint effort by ten European biomedical sciences research infrastructures in which
the project partners will develop a shared e-infrastructure—the technical bridges—
to allow interoperability between data and services in the biological, medical,
translational and clinical domains; One Mind, which has the vision of a
technology-enabled data-sharing community focused on psychiatric disease and
brain injury, brought together through a federated data platform; the Allen Brain
Atlas, a growing collection of online public resources integrating extensive gene
expression and neuroanatomical data, including that of humans, complete with a
novel suite of search and viewing tools; ELIXIR, which unites Europe’s leading life
science organizations in managing and safeguarding the massive amounts of data
being generated every day by publicly funded research; and ENIGMA (Enhancing
Neuro-Imaging Genetics through Meta-Analysis), which brings together
researchers in imaging genomics to understand brain structure and function based
on MRI, DTI, fMRI and GWAS data.
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Changing the Culture
Far-seeing higher educational establishments such as the EPFL have been devel-
oping strategies of recruitment and faculty development that bring engineering and
ICT together with life and clinical sciences in preparation for such a revolution.
The public will need to be convinced of the privacy issues, and researchers will
need to acknowledge that it is ideas and not just data that generate Nobel Prize-
winning work. Finally, politicians and industrialists will need to be convinced that
there are substantial efficiency savings to bemade by preventing the endless repetition
of underpowered studies with unrepeatable results that characterize much of present-
day life science. They will presumably be open to exploiting the added value that
federating data offers at no extra cost and to the business opportunities that arise from
developing, installing and maintaining local infrastructures to feed big data-based
medical and health sciences research on a global scale (Hood and Friend 2011).
Acknowledgments This work benefited from funding by the European Union’s Seventh Frame-
work Programme (FP7/2007–2013) under grant agreement no. 604102 (Human Brain Project).
Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s)
and source are credited.
The images or other third party material in this chapter are included in the work’s Creative
Commons license, unless indicated otherwise in the credit line; if such material is not included in
the work’s Creative Commons license and the respective action is not permitted by statutory
regulation, users will need to obtain permission from the license holder to duplicate, adapt or
reproduce the material.
References
Alagiannis I, Borovica R, BrancoM, Idreos S, Ailamaki A (2012) NoDB: efficient query execution
on raw data files. In: ACM SIGMOD international conference on management of data, ACM,
978-1-4503-1247-9/12/05
Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of
Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J
Neuropathol Exp Neurol 71:266–273
Brabham DC (2008) Crowdsourcing as a model for problem solving: an introduction and cases.
Convergence Int J Res New Media Technol 14:75–90
Brownstein JS, Freifeld CC, Reis BY, Mandl KD (2008) Surveillance sans frontieres: internet-
based emerging infectious disease intelligence and the HealthMap project. PLoS Med 5:e151.
doi:10.1371/journal.pmed.0050151
Chiang G-T, Clapham P, Qi G, Sale K, Coates G (2011) Implementing a genomic data manage-
ment system using iRODS. BMC Bioinformatics 12:361
CMS Collaboration, Chatrchyan S, Khachatryan V, Sirunyan AM, Tumasyan A, Adam W,
Aguilo E, Bergauer T, Dragicevic M, Er€o J, Fabjan C, Friedl M, Fru¨hwirth R, Ghete VM,
Hammer J, Hoch M, H€ormann N, Hrubec J, Jeitler M, Kiesenhofer W, Knu¨nz V, Kramme M,
Kra¨tschmer I, Liko D, Majerotto W, Mikulec I, Pernicka M, Rahbaran B, Rohringer C,
Rohringer H, Sch€ofbeck R, Strauss J (2012) Observation of a new boson at a mass of
125 GeV with the CMS experiment at the LHC. Phys Lett B 716:30–61
Federating and Integrating What We Know About the Brain at All Scales:. . . 169
Cross-Disorder Group of the Psychiatric Genomics Consortium (2004) Identification of risk loci
with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet
381:1371–1379
Goldstein DB (2009) Common genetic variation and human traits. N Engl J Med 360:1696–1698
Gymrek M, McGuire AL, Golan D, Halperin E, Erlich Y (2012) Identifying personal genomes by
surname inference. Science 339:321–324
Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C (2013) Novel data-mining
methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. doi:10.
1038/clpt.2013.125
Hay A, Tansley S, Tolle K (2009) The fourth paradigm: data-intensive scientific discovery.
Microsoft, Redmond, WA. ISBN 978-0-9825442-0-4
Hill SL, Wang Y, Riachi I, Schurmann F, Markram H (2012) Statistical connectivity provides a
sufficient foundation for specific functional connectivity in neocortical neural microcircuits.
Proc Natl Acad Sci USA 109:E2885–E2894
Hodgkin AL, Huxley AF (1952) A quantitative description of membrane current and its applica-
tion to conduction and excitation in nerve. Physiology 117:500–544
Hood L, Friend SH (2011) Relevance of network hierarchy in cancer drug-target selection. Nat
Rev Clin Oncol 8:184–187
Indiveri G, Linares-Barranco B, Hamilton TJ, van Schaik A, Etienne-Cummings R, Delbruck T,
Liu S-C, Dudek P, Ha¨fliger P, Renaud S, Schemmel J, Cauwenberghss G, Arthur J, Hynna K,
Folowosele F, Saighi S, Serrano-Gotarredona T, Wijekoon J, Wang Y, Boahen K (2011)
Neuromorphic silicon neuron circuits. Front Neurosci 5:73. doi:10.3389/fnins.2011.00073
Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG (2005) The evolution and pathology
of frontotemporal dementia. Brain 128:1996–2005
Khazen G, Hill SL, Schuermann F, Markram H (2012) Combinatorial expression rules of ion
channel genes in juvenile rat (Rattus norvegicus) neocortical neurons. PLoS One 7:e34786.
doi:10.1371/journal.pone.0034786
Loucoubar C, Paul R, Huret A, Tall A, Sokhna C, Trape J-F, Ly AB, Faye J, Badiane A,
Diakhaby G, Sarr FD, Diop A, Sakuntabhai A, Bureau J-F (2011) An exhaustive,
non-Euclidean, non-parametric data mining tool for unraveling the complexity of biological
systems—novel insights into malaria. PLoS One 6:e24085. doi:10.1371/journal.pone.0024085
Loucoubar C, Grange L, Paul R, Huret A, Talll A, Telle O, Roussilhon C, Faye J, Diene-Sarr F,
Trape JF, Mercereau-Puijalon O, Sakuntabhai A, Bureau JF (2013) High number of previous
Plasmodium falciparum clinical episodes increases risk of future episodes in a sub-group of
individuals. PLoS One 8:e55666. doi:10.1371/journal.pone.0055666
Marks P (2007) Massive science experiments pose data storage problems. New Sci 196:28–29
Marx V (2013) The big challenges of big data. Nature 498:255–260
Peck C, Markram H (2008) Identifying, tabulating, and analyzing contacts between branched
neuron morphologies. IBM J Res Dev 52:43–55
Pfeil T, Grubl A, Jeltsch S, Muller E, Muller P, Petrovici MA, Schmuker M, Bruderle D,
Schemmel J, Meier K (2013) Six networks on a universal neuromorphic computing substrate.
Front Neurosci 7:11. doi:10.3389/fnins.2013.00011
Rajasekar A, Moore R, Hou CY, Lee CA, de Torcy A, Wan M, Schroeder W, Chen SY, Gilbert L,
Tooby P, Zhu B (2010) iRODS primer: integrated rule-oriented data system. Synthesis lectures
on information concepts, retrieval, and services. Morgan & Claypool, San Rafael, 143p
Ramaswamy S,Hill SL, King JG, Schurmann F,WangY,MarkramH (2012) Intrinsicmorphological
diversity of thick-tufted layer 5 pyramidal neurons ensures robust and invariant properties of in
silico synaptic connections. J Physiol (Lond) 590:737–752. doi:10.1113/jphysiol.2011.219576
Sch€ols L, Bauer P, Schmidt T, Schulte T, Riess O (2012) Autosomal dominant cerebellar ataxias:
clinical features, genetics, and pathogenesis. Lancet Neurol 3:291–304
Zhang B, Gaiteri C, Bodea L-G, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L,
DobrinR, Fluder E, ClurmanB,Melquist S, NarayananM, Suver C, ShahH,MahajanM,Gillis T,
Mysore J,MacDonaldME,Lamb JR, Bennett DAB,MolonyC, StoneDJ,GudnasonV,MyersAJ,
Schadt EA, NeumannH, Zhu J, Emilsson V (2013) Integrated systems approach identifies genetic
nodes and networks in late-onset Alzheimer’s disease. Cell 153:707–720
170 R. Frackowiak et al.
